Delivery Order SPE2DB20D9354-SPE2DB25FX7Y7
- Not listed
- The Defense Logistics Agency awarded a $1,547.40 delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of XOLAIR 150 mg/ml syringes. The contract is firm fixed-price with an ultimate completion date of September 18, 2025, and carries no set-aside designation. This delivery order falls under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the DLA valued at approximately $500 million...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order valued at $4,642.20 by the Defense Logistics Agency (DLA) on September 4, 2025. The delivery order is for Xolair 150 mg/ml syringes, with an ultimate completion date of September 25, 2025. This award carries no set-aside designation, allowing the vendor to compete on equal footing in the federal procurement marketplace. The place of...
- The Defense Logistics Agency awarded a firm fixed-price delivery order valued at $3,094.80 to DMS Pharmaceutical Group Inc. for the supply of Xolair 150 mg/ml syringes. DMS Pharmaceutical Group, a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, will perform the delivery at its Park Ridge location with an ultimate completion date of October 2, 2025. This delivery order was issued without a set-aside designation, leveraging the company's competitive capabilities...
- The Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order valued at $7,737.00 to DMS Pharmaceutical Group Inc. for the supply of Xolair 150 mg/ml syringes. DMS Pharmaceutical Group, a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, will perform the delivery at its location in Park Ridge, IL. This delivery order was issued without a set-aside designation and carries an ultimate completion date of September 16, 2025. The award represents a...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order by the Defense Logistics Agency valued at $38,685.00 for XOLAIR 75 MG/0.5 ML syringes. The contract is structured as a firm fixed-price delivery order with an ultimate completion date of October 2, 2025, and was executed on September 11, 2025. This award carries no set-aside designation, allowing DMS Pharmaceutical Group to compete on an open basis...
- The Defense Logistics Agency awarded DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, a delivery order for XOLAIR 150 MG/ML syringes valued at $3,094.80. The contract, which was awarded on September 8, 2025, with an ultimate completion date of September 29, 2025, carries firm fixed-price terms and does not utilize a set-aside designation. This delivery order was issued under DMS Pharmaceutical Group's larger Indefinite...
- The Defense Logistics Agency awarded a $37.5K firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xolair 300 mg/2 mL syringes. This delivery order, which is expected to be completed by September 11, 2025, was issued without a set-aside designation. DMS Pharmaceutical Group is performing the work at its Park Ridge, Illinois location and will deliver this biologic medication to...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order valued at $4,642.20 by the Defense Logistics Agency's Medical Supply Chain for the supply of Xolair 150 mg/ml syringes. The award, issued on August 29, 2025, with an ultimate completion date of September 22, 2025, carries no set-aside designation. This delivery order is issued under DMS Pharmaceutical Group's larger single-award...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $77,370 by the Defense Logistics Agency's Medical Supply Chain on September 9, 2025. The contract covers the supply of XOLAIR 150 mg/ml syringes, a biologic medication used to treat moderate to severe allergic asthma and chronic idiopathic urticaria. This firm fixed-price delivery order, with an ultimate completion date of September 30, 2025,...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $2,321.10 by the Defense Logistics Agency (DLA) on August 27, 2025, for the supply of Xolair 150 mg/ml syringes. The contract, awarded without set-aside designation, carries a firm fixed-price structure with an ultimate completion date of September 18, 2025. This delivery order is issued under DMS Pharmaceutical Group's existing Indefinite...
- SPE2DB20D9354Indefinite Delivery Contract
- SPE2DB20D9354-SPE2DB25FX7Y7Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $7,737.00 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of XOLAIR 150 mg/ml syringes. This firm fixed-price delivery order, issued on September 10, 2025, is scheduled for ultimate completion by October 1, 2025, with performance taking place at the awardee's Park Ridge facility. The contract was awarded without a set-aside designation, demonstrating DMS Pharmaceutical Group's competitive strength in the federal pharmaceutical procurement marketplace. This delivery order is issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the Defense Logistics Agency under the SPE2DB program, a $499.9 billion vehicle valid through November 2026 that authorizes the agency to procure a comprehensive range of pharmaceutical products and medical supplies supporting Department of Defense healthcare facilities worldwide. XOLAIR (omalizumab), a biologic medication used primarily for asthma and chronic idiopathic urticaria treatment, represents one of many specialty pharmaceutical items available through this strategic partnership. As a key supplier within the federal pharmaceutical supply chain, DMS Pharmaceutical Group has consistently delivered diverse medical products ranging from prescription medications and biologics to vaccines and specialty treatments across military health systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $7.7k | 9/10/25 |